Marek Health Review: Seven Named Pharmacies, and a Peptide Catalogue Nobody Can Open

Eight of the thirteen are on a list FDA publishes

FDA maintains a page titled "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks", content current as of 22 April 2026. ¹ It sets out substances the agency reviewed when they were nominated for the 503A bulks list and for which it identified a potential significant safety risk, together with the risk it found.

Read Marek's thirteen against it.

Eight for thirteen. FDA's entries are not identical and are not vague. On BPC-157: compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities". On KPV — which Marek sells inside a combination capsule with BPC-157 — the agency "has not identified any human exposure data on drug products containing KPV administered via any route of administration". On CJC-1295, the same immunogenicity language. ¹

None of those molecules complies with a USP or NF monograph, is a component of an approved drug, or appears on the 503A bulks list — the three conditions under which a state-licensed pharmacy may lawfully compound with a bulk substance at all. ² If the distinction between the two compounding regimes is unfamiliar, 503A and 503B are not two words for the same thing.

The remaining five are the interesting ones, and they are interesting for the opposite reason: four of the five are, or were, the active ingredient of a drug with a US approval. That is precisely the status the other eight do not have.

"FDA-approved pharmacies"

Here is what the live site does say about how your medication is made. This is on the rendered home page, in the list of what the $299 intake buys:

Delivered To Your Door: Exclusive access to Marek Health's FDA-approved pharmacies and supplement dispensaries.

And on /faqs, at the end of an otherwise careful explanation of why compounded orders take days rather than minutes:

We only use 503A/503B FDA Approved and Audited compounding pharmacies as our fulfillment partners.

And in the JSON-LD structured data served on /trt and /testosterone, where it is machine-readable rather than merely readable: "Coordination of delivery from FDA-approved pharmacies and supplement dispensaries."

There is no such thing as an FDA-approved pharmacy. FDA approves drug products — a new drug application, a National Drug Code, a label the agency has reviewed for that specific product. Under section 503B it registers outsourcing facilities, which subjects them to inspection and to current good manufacturing practice and approves nothing. Under 503A it does not license pharmacies at all; states do. And no compounded preparation from any pharmacy holds an approval, which is why the compounded preparation is not the trial drug.

The phrase "503A/503B" compresses the two regimes into one label. A given vial is made under one or the other; the record-keeping, the inspection regime and the limits on what may be compounded all differ.

The part where naming your pharmacy pays off

Now the disclosure that makes this review possible, and it is genuinely the best in the category. Marek's terms and conditions contain this:

Our Services provides access to prescription fulfillment services offered by the following pharmacies: Anazao Health Corporation (5710 Hoover Boulevard, Tampa, FL 33634), ReviveRX (3831 Golf Dr A, Houston, TX 77018), TMC Acquisition, LLC. DBA Tailor Made Compounding (200 Moore Dr, Nicholasville, KY 40356), Empower Clinic Services LLC DBA Empower Pharmacy (7601 North Sam Houston Pkwy W Ste 100, Houston, TX 77064), DYL LLC DBA South Lake Pharmacy (38101 5th Ave, Zephyrhills, FL 33542), Honeybee Health, Inc. (3515 Helms Ave, Culver City, CA 90232), and Strive Pharmacy (1275 E Baseline Rd #104, Gilbert, AZ 85233) (the "Pharmacies") … You agree and understand that your prescription(s) may be filled by and transferred between any of the Pharmacies

Seven companies, seven street addresses, seven phone numbers, and a plain statement that your prescription may move between them. Most telehealth brands in this category name none.

The point of naming them is that a reader can check. So this review checked all seven against the live FDA warning-letter index.

Empower Clinic Services, LLC dba Empower Pharmacy — the address on FDA's letter is 7601 N Sam Houston Pkwy W Ste 100, Houston, TX 77064, character for character the address Marek prints. Warning letter 700964, dated 2 April 2025, following an inspection from 24 September to 4 October 2024. The body states that investigators "noted serious deficiencies in your practices for producing drug products, which put patients at risk", and that drug products "intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health". ¹⁹ The datatable carries no close-out date.

AnazaoHealth Corporation received a warning letter dated 18 August 2021 concerning its registration as a 503B outsourcing facility. ²⁰ That letter is addressed to 7465 W. Sunset Road, Suite 1200, Las Vegas, NV 89113 — a different facility in a different state from the Tampa address in Marek's terms. It is reported here as the same corporation at a different registered site, and nothing more is claimed from it.

ReviveRX, Tailor Made Compounding, South Lake Pharmacy, Honeybee Health and Strive Pharmacy each returned zero rows.

A warning letter discloses; it does not disqualify, and most compounders of any size have one somewhere in their history. What is uncomfortable here is the pairing: the one quality claim Marek makes about these seven companies is that they are "FDA Approved and Audited". "Audited" turns out to be true in a way the sentence did not intend.

Four checkable errors on the pages nobody can read

Grading the catalogue is grading a document the public has been given and not shown. It is worth doing anyway, because the errors are the specific, checkable kind.

Tesamorelin: the citation is off by three years and the placebo arm is reversed

The card reads: "Tesamorelin in HIV-Infected Patients with Abdominal Fat — New England Journal of Medicine (2010): Phase 3 (n=412): 15.2% VAT reduction vs -0.5% placebo at 26 weeks."

The 412-patient phase 3 is NCT00123253, and it was published in the New England Journal of Medicine in 2007. ^{6 7} Visceral adipose tissue measured by CT fell 15.2% on tesamorelin — and rose 5.0% on placebo. Not a 0.5% fall. The direction of the comparator has been flipped and its size cut by a factor of ten, which happens to make the drug's margin look smaller rather than larger, so this is carelessness rather than salesmanship. It is still wrong on a page selling the drug.

The second card reads: "Tesamorelin and Cognition in Older Adults — The Lancet Healthy Longevity (2021): Improved verbal memory and executive function over 20 weeks in older adults including those with MCI."

A PubMed search of The Lancet Healthy Longevity for tesamorelin or growth-hormone-releasing hormone returns zero records. The trial being described — 20 weeks, verbal memory and executive function, adults with mild cognitive impairment and healthy older adults — is Baker et al., Archives of Neurology, 2012. ⁹ Right result, wrong journal, wrong decade.

Underneath the citations sits the swap this category always makes. The approved label reads: "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy," and, under Limitations of Use, "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." ⁸ Marek at least labels the metabolic-syndrome use "(off-label)". Outside HIV the registry holds one phase 2 study, 60 participants, completed January 2012. ¹⁰ This is the recurring shape in the growth-hormone secretagogue family.

SS-31: the wrong half of a disease, and a drug that got approved

The card says elamipretide is "In Phase II/III for HFpEF and Barth syndrome" and lists "Phase II evidence showing improved exercise capacity" and "Favorable safety in completed trials".

Three things have moved.

There is no HFpEF trial. Every registered elamipretide heart-failure study is in heart failure with reduced ejection fraction or in acute decompensation — NCT02788747, 71 participants, "Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction". ¹³ Preserved and reduced ejection fraction are different diseases with different treatments.

The phase 3 missed. MMPOWER-3 randomised 218 people with primary mitochondrial myopathy. Its published report states the study "did not meet its primary endpoints assessing changes in the 6MWT and PMMSA total fatigue score" — the six-minute-walk difference was −3.2 metres, 95% CI −18.7 to 12.3, p = 0.69. ¹⁴ "Phase II evidence showing improved exercise capacity" is true only if you stop reading before the phase 3. That is what a failed trial looks like, and it is why phase 2 results are not a result.

The molecule has an approval now. FORZINITY (elamipretide hydrochloride) injection carries a current FDA label from Stealth BioTherapeutics: "FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint." ¹¹ The Barth-syndrome trial behind it, TAZPOWER, enrolled twelve people. ¹²

Marek sells a compounded copy of that molecule for "Age-related mitochondrial dysfunction", a population no trial of it has ever studied.

CJC-1295 and ipamorelin: a hormone level is not a body

The stack is described as "Most widely prescribed peptide stack in optimization medicine", with the benefit "Improved lean mass, reduced visceral fat".

The pharmacology half checks out. Teichman et al. gave CJC-1295 to healthy adults and reported dose-dependent increases in mean plasma growth hormone of two- to ten-fold lasting six days or more, IGF-1 up 1.5- to three-fold for nine to eleven days, and an estimated half-life of 5.8 to 8.1 days. ¹⁸ Marek's "~6 to 8 day half-life" is that paper's number.

What that study measured was hormone concentrations in blood. Lean mass and visceral fat are different objects — the distinction between a surrogate marker and an outcome.

For those outcomes:

1. Complete

   CJC-1295 registered trials worldwide

   Exactly one — NCT00267527, phase 2, HIV patients with visceral obesity, 120 participants, ConjuChem. Status: TERMINATED, 2006.

2. Complete

   Ipamorelin completed phase 2 trials

   Two — both post-operative ileus and gastrointestinal recovery, sponsored by Helsinn, 117 and 320 participants.

3. 3 — Not reached

   A trial of the stack in body composition

   None registered, anywhere, for either molecule.

^{15 16 17}

BPC-157: the one that gets it right

And then the entry that should be famous, and is currently visible to nobody:

Synthetic 15-amino-acid pentadecapeptide derived from gastric juice glycoprotein. Strong tissue-protective and healing properties across multiple organ systems in animal models. No completed human clinical trials; all evidence is preclinical.

Its efficacy bullet reads "Accelerated tendon/ligament/muscle repair (animal models)", and its serious-risks list opens with "No completed human safety trials".

That is correct. A PubMed search for BPC-157 or "BPC 157" in title or abstract, restricted to the randomised-controlled-trial publication type, returns zero records as of August 2026. ³ The registry holds a phase 1 pilot whose status has read UNKNOWN since a listed completion of March 2016, with no results posted ⁴, and a phase 2 hamstring-strain trial that began recruiting on 2 February 2026 and estimates completion in 2028. ⁵ The gap between what people report about recovery peptides and what has been tested is the whole subject, and Marek's own copy states the gap plainly.

Two things it still does not say. It does not mention FDA's safety-risk entry for BPC-157, which bears directly on the four dosage forms offered — an injectable vial, a 1000 mcg oral capsule, a 500 mcg/mL nasal spray and a combination capsule with KPV. No registered study has tested an oral or nasal route; route changes the drug. And it does not say any of it where a customer could read it.

What it adds up to

Set the two halves beside each other.

On one side: seven pharmacies named with addresses, a plain statement that Marek is a platform and not a clinic, a published $299 entry price with a stated $450 lab minimum, a mandatory comprehensive panel before anything is prescribed, a direct-pay acknowledgment that forecloses insurance ambiguity, and an unusually frank explanation of why a compounded order takes days.

On the other: a catalogue of thirteen peptides that exists, is finished, is downloaded into every visitor's browser, and is rendered nowhere; eight of those thirteen named on FDA's own safety-risk page; a promise of "FDA-approved pharmacies" on the home page and inside the structured data; and a warning letter over insanitary conditions at one of the seven companies the terms name.

The company that wrote "No completed human clinical trials; all evidence is preclinical" knows exactly what a reader is owed. It has already written it down. It is a claim outrunning its evidence only in the places where the catalogue reaches — and everywhere else, it is a claim with no molecule attached at all.